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ABSTRACT
Background Several scoring systems have been used to
predict mortality in patients with community-acquired
pneumonia. The properties of commonly used risk
stratification scales were systematically reviewed.
Methods MEDLINE and EMBASE (January
1999eOctober 2009) were searched for prospective
studies that reported mortality at 4e8 weeks in patients
with radiographically-confirmed community-acquired
pneumonia. The search focused on the Pneumonia
Severity Index (PSI) and the three main iterations of the
CURB (confusion, urea nitrogen, respiratory rate, blood
pressure) scale (CURB-65, CURB, CRB-65), and test
performance was evaluated based on ‘higher risk’
categories as follows: PSI class IV/V, CURB-65 (score
$3), CURB (score$2) and CRB-65 (score$2). Random
effects meta-analysis was used to generate summary
statistics of test performance and receiver operating
characteristic curves were used for predicting mortality.
Results 402 articles were screened and 23 studies
involving 22 753 participants (average mortality 7.4%)
were retrieved. The respective diagnostic odds ratios for
mortality were 10.77 (PSI), 6.40 (CURB-65), 5.97 (CRB-
65) and 5.75 (CURB). Overall, PSI had the highest
sensitivity and lowest specificity for mortality, CRB-65was
the most specific (but least sensitive) test and CURB-65/
CURB were between the two. Negative predictive values
for mortality were similar among the tests, ranging from
0.94 (CRB-65) to 0.98 (PSI), whereas positive predictive
values ranged from 0.14 (PSI) to 0.28 (CRB-65).
Conclusions The current risk stratification scales (PSI,
CURB-65, CRB-65 and CURB) have different strengths
and weaknesses. All four scales had good negative
predictive values for mortality in populations with a low
prevalence of death but were less useful with regard to
positive predictive values.
BACKGROUND
Community-acquired pneumonia (CAP) is
a common cause of hospital admission and
a leading cause of death in the UK.1 The overall
mortality of CAP varies, with higher rates of death
seen in those judged to have severe pneumonia.2e5
A reliable method of assessing the severity of
pneumonia may potentially improve the triage or
initial management of patients by helping clini-
cians determine whether close monitoring and
aggressive treatment is more appropriate than
conservative management. However, accurately
assessing the severity of pneumonia can be chal-
lenging, so a number of scales based on prognostic
factors have been designed to identify patients at
high risk of death, as well as those at low risk who
may require less of a watchful eye.
The most notable scales are the CURB-65
(confusion, urea nitrogen, respiratory rate, blood
pressure, age $65 years) which is recommended by
the British Thoracic Society5 and the Pneumonia
Severity Index (PSI) which originates from the
USA.6 Different iterations of the CURB-65 are
available, including the CRB-65 which may be
particularly suited for community use as it relies
on clinical history and examination without
requiring blood urea measurements,7 and the
CURB score which excludes age as part of its
criteria, thus reducing emphasis on chronological
age as a prognostic factor.8
In this review we aimed to systematically
retrieve and appraise the available data on the PSI
and the three main iterations of the CURB scoring
system (CURB, CRB-65, CURB-65) in order to
determine the ability of each test to correctly
predict mortality in patients with pneumonia.
Although we are aware of a multitude of individual
studies in different settings, the comparative
performance of these scales has yet to be
summarised in a meta-analysis.
METHODS
Search strategy
Ovid SP was used to search PubMed and EMBASE
from 1999 up to October 2009 using the terms
(Pneumonia and (Sever* or Predict* or prognos*) and
(scale or score or assessment or index) and (mortality
or survival or death) and (community-acquired)).mp.
The bibliographies of included studies were checked
for any other relevant articles and the authors were
contacted for further information where necessary.
Eligibility criteria
Two reviewers initially checked the title and
abstracts against the following inclusion and
exclusion criteria.
Inclusion criteria
< English language journal publication
< At least 100 participants
< Prospective studies
< Reporting patient outcomes after the use of
a pneumonia severity scale
< Community-acquired pneumonia, which may
include residents of nursing homes
< Randomised controlled trials where any single
intervention arm fulﬁlled inclusion criteria; we
did not consider trials comparing different
antibiotics.
< An additional table is
published online only. To view
this file please visit the journal
online (http://thorax.bmj.com).
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Exclusion criteria
< Less than 100 participants in the study
< Based in the community (without radiological and laboratory
tests), or if recruitment was restricted to patients on the
intensive care unit without considering other hospitalised
patients. However, we accepted studies that reported fully on
all hospitalised patients (in intensive care as well as general
wards).
< Hospital-acquired pneumonia
< Studies that looked at outcomes of speciﬁc types of
pneumonia such as legionella or viral rather than commu-
nity-acquired pneumonia in general
< Studies that relied entirely on speciﬁc biomarkers without
using a clinical risk stratiﬁcation scale
< Retrospective studies.
From the above we then obtained full-text versions of poten-
tially relevant articles and carried out a more detailed screening
process. In conjunction with the above criteria, studies were
included only if:
< Pneumonia was deﬁned by signs, symptoms and chest x-ray
< Follow-up mortality data were available at 4e8 weeks after
presentation
< Reporting of mortality according to parameters of severity
scale (PSI, CURB-65, CRB-65, CURB)
< Enrolment of patients in the 10-year period spanning
1999e2009 (the CURB-65 and its different iterations only
became available after 1999 and we wanted to ensure that
comparisons of the PSI and CURB-65 scales were based on
patients recruitedwithin the same time period; this was aimed
at reducing the possibility of confounding where any
differences in the performance of the severity scales might
have stemmed from time-related changes in the epidemiology,
microbiology or treatment of pneumonia).
Validity assessment
Study validity was assessed using a checklist based on published
opinion regarding the key components of prognostic studies.9
The list was based on clear reporting of the following items:
< Patient selection criteria
< Diagnostic criteria for pneumonia
< Loss to follow-up
Potentially relevant trials identified, 
and titles and abstracts screened
(n=402)
Further checking of full text of
potentially relevant studies (n=66) 
Excluded on basis of title and abstract for clearly not
fulfilling inclusion criteria on basis of outcomes
measured, study design,severity scale or population. 
(n= 336)
25 excluded for various reasons such as retrospective 
studies, absence of mortality  data, or did not report
on PSI/ CURB-6, CRB-65, or CURB.
Potentially relevant studies (n=41)
Studies included in review (n=23)
18 excluded studies, comprising of
Incomplete reporting of raw data = 6
No Chest X-ray validation =1
Did not report mortality at 4-8 weeks = 10
Duplicate report =1
Figure 1 Flowchart showing study selection for pneumonia severity
scales. CURB, confusion, urea nitrogen, respiratory rate, blood pressure;
PSI, Pneumonia Severity Index.
Table 1 Study characteristics
Study ID Country Setting
Severity scales
assessed
Time of outcome
ascertainment
No of
patients Age (years) % Male
Aujesky14 USA 32 hospital emergency departments PSI, CURB, CURB-65 30 days 3181 63 (mean) 48
Barlow15 UK University teaching hospital CURB-65, CRB-65 30 days 419 74 (median) 47
Bauer16 Germany 10 hospitals and outpatient clinics CRB-65, CURB 14, 30 and 180 days 2184 62.6 (mean) 56.6
Capelastegui17 Spain Teaching hospital CURB-65, CRB-65 30 days 1776 62 (mean) 63
Charles18 Australian 6 university teaching hospitals PSI, CURB-65 30 days 882 76% >50
years
61
Etizion19 Israel University hospital-based medical centre PSI 30 days 591 63.5 (mean) 44.5
Ewig8 Spain University hospital PSI, CURB 30 days 592 for CURB,
489 for PSI
67.8 (mean) 66
Gutierrez20 Spain University teaching hospital PSI 30 days 493 56.6 (mean) 62.5
Huang21 USA Community, teaching hospital and ED PSI, CURB-65 30 days 1651 65 (mean) 52
Johnstone22 Canada 6 hospitals PSI 30 days 3284 69 (mean) 53
Kruger23 Germany 10 clinical centres CRB-65 14, 30 & 180 days 1671 61 (mean) 55
Lim5 UK, New Zealand,
Netherlands
University teaching hospital PSI, CURB, CURB-65, CRB-65 30 days 1068 64 (mean) 51
Man24 Hong Kong Emergency department PSI, CURB-65, CRB-65 30 days 1016 72 (mean) 57
Menendez25 Spain University teaching hospital PSI, CURB-65, CRB-65 30 days 453 67 (mean) 62
Myint4 UK University teaching hospital CURB-65, CRB-65, CURB 42 days 195 75 (median) 57
Myint26 UK 3 UK hospitals CURB-65 42 days 190 76 (median) 53
Pilotto27 Italy Hospital PSI 30 days 134 78.7 (mean) 66
Renaud28 France 16 emergency departments PSI 28 days 925 71 (median) 64
Renaud29 France, Spain, USA University teaching hospital PSI 30 days 853 65% >51
years
56
Reyes Calzada30 Spain 4 public hospitals PSI 30 days 425 69 (mean) 64.5
Schuetz31 Switzerland University teaching hospital PSI, CURB-65, CRB-65 30 days 373 73 (median) 60
van der Eerden32 Netherlands Teaching hospital PSI 30 days 260 64 (mean) 53.8
Zuberi33 Pakistan University teaching hospital CURB-65, CRB-65 30 days 137 60.4 (mean) 74
CRB-65, confusion, respiratory rate, blood pressure, age $65 years; CURB, confusion, urea nitrogen, respiratory rate, blood pressure; CRB-65, confusion, respiratory rate, blood pressure, age
$65 years; CURB, confusion, urea nitrogen, respiratory rate, blood pressure; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure, age$65 years; PSI, Pneumonia Severity Index.
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< Methods used to ascertain outcome
< Management protocol used in treating pneumonia (eg,
antibiotic regimen)
Data abstraction
Two reviewers assessed the eligibility and extracted numerical
outcomes data from the included studies. The reviewers obtained
full consensus on inclusion of the studies and data extraction
after resolving any discrepancies through discussion with team
members. Authorswere contacted if any items required clariﬁcation.
Study characteristics
Geographical location and setting, sample size, age and gender of
participants, type of prognostic scale and mortality rate
according to classiﬁcation of severity were recorded.
Quantitative data synthesis and sensitivity analysis
Patients were classiﬁed according to risk score and data on
mortality were extracted. For each study the numbers of patients
and deaths were recorded, with ‘higher risk or severe’ dichotom-
ised categories comprising PSI (class IV and V), CURB-65 (score
$3), CURB (score$2) andCRB-65 (score$2). Statistical analysis
was carried out using R-DiagMeta,10MetaAnalyst11 and RevMan
5.024 (Nordic Cochrane Center, Copenhagen, Denmark). Pooled
sensitivities, speciﬁcities, diagnostic odds ratios (OR) and positive
and negative predictive values were calculated using the random
effects model (which takes into account the variability between
studies).12 The summary receiver operating characteristic curves
(SROC) for each severity scale were generated with the bivariate
random effects approach.10 Statistical heterogeneity was assessed
using the I2 statistic, with I2 values>50% indicating a substantial
level of heterogeneity.13
RESULTS
The study selection ﬂowchart is shown in ﬁgure 1. Twenty-three
studies were included in the analysis,14e33 with some studies
reporting more than one risk stratiﬁcation scale. Sixteen studies
Figure 2 Receiver operating characteristics space illustrating performance of scoring systems at identifying patients at risk of death. (A) Paired
sensitivity and specificity with SROC curves giving an indirect comparison of all four scoring systems. (B) Paired specificity and sensitivity of PSI
versus CURB-65 in predicting mortality in head to head studies. (C) Paired specificity and sensitivity of PSI versus CRB-65 in predicting mortality in
head to head studies. CRB-65, confusion, respiratory rate, blood pressure, age $65 years; CURB, confusion, urea nitrogen, respiratory rate, blood
pressure; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure, age $65 years; PSI, Pneumonia Severity Index.
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covered PSI, 12 CURB-65, 10 CRB-65 and 5 CURB. For direct
comparisons of the severity scales in the same patient dataset,
7 tested PSI versus CURB-65, 4 tested PSI versus CRB-65 and
2 studied PSI versus CURB. Table 1 and online table show the
characteristics of the studies included in the meta-analysis.
The total sample size from the 23 studies was 22 753 partic-
ipants with 1680 deaths, giving an average mortality rate of
7.4%. Sample sizes ranged from 134 to 3181 participants. Studies
were carried out mainly in emergency department and hospital
settings in Europe and North America, with a smaller proportion
of data available from Australia, Hong Kong and Pakistan. The
average age of participants in the studies was typically around
60 or 70 years. For the validity assessment we found the risk of
bias to be a particular issue with ascertainment of mortality.
Only 14 of the 23 studies gave details on the methods used in
conﬁrming whether participants had died during the follow-up
period (see online table). Lack of information on patient
management was another major potential source of bias as there
was little information on the interventions used in treating
pneumonia and whether antibiotic use was consistent both
within a study and between different studies.
Indirect and direct comparisons of the ability to identify patients
at risk of death
The paired sensitivities (proportion of patients who subse-
quently die who were correctly classiﬁed as ‘higher risk’) and
speciﬁcities (proportion of survivors who were correctly classi-
ﬁed as not being in the ‘higher risk’ category) of each study are
shown with the SROC curves for the severity scale in ﬁgure 2A.
Data on the studies with direct comparisons are shown in
ﬁgure 2B and C, with 7 studies evaluating PSI versus CURB-65
and 4 studies comparing PSI with CRB-65 (the results for other
direct comparisons are not shown owing to the small number of
studies). Both the direct and indirect comparisons consistently
indicate that PSI is more sensitive but less speciﬁc than CURB-
65, CURB or CRB-65 in identifying those who subsequently die.
Forest plots of the raw data and estimated sensitivities and
speciﬁcities from each study are shown in ﬁgure 3AeD. Pooled
estimates of sensitivities, speciﬁcities, diagnostic ORs and posi-
tive and negative predictive values were measured for each scale
and these results are shown in table 2. There was signiﬁcant
heterogeneity for the pooled estimates.
As there were only a relatively small proportion of deaths, the
negative predictive values of all four scales were similarly impres-
sive, ranging from0.94 (CRB-65) to 0.98 (PSI). The low prevalence
of death also accounts for the somewhat low positive predictive
values ranging from 0.14 (PSI) to 0.28 (CRB-65) (table 2).
Estimates of clinical impact of each severity scale
Measures of the clinical impact of risk stratiﬁcation (such as
positive and negative predictive values) depend on the under-
lying rate of pneumonia-related deaths. Figure 4A shows the
absolute number of false negatives (number of patients wrongly
classiﬁed as non-severe) according to severity scale per 1000
patients with pneumonia. The PSI had the lowest false negative
rate, meaning that the test is able to correctly identify patients
who have non-severe pneumonia and are at low risk of death.
Figure 4B shows the absolute number of false positives (number
of patients misclassiﬁed as ‘high risk’) per 1000 patients with
pneumonia, according to test. This illustrates that the PSI errs
on the side of caution by judging relatively more survivors as
being at ‘high risk’, whereas the CURB-65 and its iterations are
more speciﬁc in correctly classifying patients who have a greater
likelihood of death. These ﬁgures also conﬁrm that the absolute
impact of test performance varies with the mortality rate and
that the differences between tests become more apparent in
populations with high proportions of pneumonia-related deaths.
DISCUSSION
To our knowledge, this is the ﬁrst systematic review and
meta-analysis covering the comparative test performance of
pneumonia severity scales that are in common clinical use.
Current risk stratiﬁcation scales (PSI, CURB-65, CRB-65 and
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Figure 3 Forest plots of sensitivity and specificity according to study
and prognostic scale. (A) Pneumonia Severity Index (PSI). (B) CURB-65
(confusion, urea nitrogen, respiratory rate, blood pressure, age
$65 years). (C) CRB-65 (confusion, respiratory rate, blood pressure, age
$65 years). (D) CURB (confusion, urea nitrogen, respiratory rate, blood
pressure).
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CURB) have different trade-offs and no single scale is clearly
superior on all counts. The PSI is the most sensitive test with
a low false negative rate (ﬁgure 4A), thus giving clinicians
greater conﬁdence in identifying patients who may not need
hospital admission.34 Conversely, the CURB-65, CRB-65 and
CURB scales are more speciﬁc and have higher positive predic-
tive values than the PSI, which means that a greater proportion
of patients in the ‘higher risk’ categories are correctly classiﬁed.
In theory, the poorer sensitivity of the CURB-65-based scales
means that some patients may be incorrectly diagnosed and
managed as non-severe even when they are actually at higher
risk of death. However, as there was only a relatively small
percentage of deaths (7.4%) among study participants, the
negative predictive values of these CURB-65-based tests are very
similar to those of PSI, indicating that the clinical differences
between tests are likely to be small. In situations with a low
prevalence of adverse outcomes, we can be more conﬁdent that
a ‘non-severe’ test result reliably predicts that the patient will
have a good outcome, but we are also less certain that a ‘severe’
rating genuinely predicts death.35 This is illustrated by the range
of positive predictive values from 0.14 (PSI) to 0.28 (CRB-65).
The practical aspects and resource implications of the chosen
scoring system should also be considered. The PSI involves
a detailed history, physical examination, venous blood sampling,
arterial blood gas measurements and chest x-ray, thus requiring
the physician to gather a total of 12 parameters from the history
and examination as well as 7 parameters derived from further
investigations.6 Although most of the parameters for the PSI are
available in hospital settings and can be worked out with a web-
based PSI calculator,36 busy clinicians in emergency departments
may end up not bothering to estimate the PSI or may rush
through the task inaccurately. However, the CURB-65-based
scales do not incorporate potentially important parameters such
as hypoxaemia and bilateral pneumonia in their scores, while the
CRB-65 (a potentially useful scale for community use) omits the
urea measurement, thus possibly reducing sensitivity.
The choice of test depends on the attitude of the health
providers regarding healthcare and resources use as well as the
rate of pneumonia-related mortality. The most sensitive and
labour-intensive test (such as the PSI) may be preferred in
resource-rich healthcare settings, particularly where pneumonia
mortality is relatively high. In certain community settings with
limited resources and where pneumonia mortality is relatively
low, the lower sensitivity of the CRB-65 is not a major disad-
vantage and its ease of use and higher speciﬁcity may help
clinicians to focus on those requiring more clinical attention.
Study limitations
There are a number of limitations in our review. There is clearly
considerable heterogeneity in the performance of the severity
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Figure 4 (A) Number of patients wrongly classified as non-severe as
a function of incidence of mortality per 1000 patients with pneumonia. (B)
Number of patients wrongly classified as severe as a function of incidence of
mortality per 1000 patients with pneumonia. CRB-65, confusion, respiratory
rate, blood pressure, age$65 years; CURB, confusion, urea nitrogen,
respiratory rate, bloodpressure; CURB-65, confusion, ureanitrogen, respiratory
rate, blood pressure, age$65 years; PSI, Pneumonia Severity Index.
Table 2 Summary statistics* of test performance for the pneumonia risk stratification scales
Severity scale
PSI (n[16 519) CURB-65 (n[11 199) CRB-65 (n[8143) CURB (n[6237)
Summary statistic
(95% CI) I2
Summary statistic
(95% CI) I2
Summary statistic
(95% CI) I2
Summary statistic
(95% CI) I2
Pooled sensitivity 0.90 (0.87 to 0.92) 59% 0.62 (0.54 to 0.70) 81% 0.33 (0.24 to 0.44) 84% 0.63 (0.49 to 0.76) 88%
Pooled specificity 0.53 (0.46 to 0.59) 98% 0.79 (0.75 to 0.83) 96% 0.92 (0.86 to 0.96) 98% 0.77 (0.68 to 0.83) 98%
Positive predictive value 0.14 (0.13 to 0.16) 75% 0.24 (0.19 to 0.30) 88% 0.28 (0.18 to 0.41) 92% 0.17 (0.14 to 0.22) 78%
Negative predictive value 0.98 (0.98 to 0.99) 46% 0.95 (0.93 to 0.97) 91% 0.94 (0.92 to 0.95) 89% 0.97 (0.96 to 0.97) 52%
Diagnostic OR 10.77 (8.29 to 13.97) 39% 6.40 (5.05 to 8.10) 56% 5.97 (3.41 to 10.44) 86% 5.75 (4.59 to 7.21) 0%
*Summary statistics consist of the pooled sensitivity, pooled specificity, positive and negative predictive values and diagnostic OR for the performance of each test in differentiating between
survivors and patients who subsequently die.
CRB-65, confusion, respiratory rate, blood pressure, age $65 years; CURB, confusion, urea nitrogen, respiratory rate, blood pressure; CRB-65, confusion, respiratory rate, blood pressure, age
$65 years; CURB, confusion, urea nitrogen, respiratory rate, blood pressure; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure, age$65 years; PSI, Pneumonia Severity Index.
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scales, which may be related to the diverse populations evalu-
ated and differences in microbiological spectrum and antibiotic
sensitivity. This affects the validity of the pooled estimates
which we presented as a secondary analysis, even though we
used a random effects model which incorporates study level
variability into the meta-analysis. Other researchers have
suggested that large degrees of heterogeneity are commonly seen
in meta-analyses of diagnostic studies.37 Closer examination of
our Forest plots did not demonstrate any consistent source to
account for the substantial heterogeneity, and we believe that
the data points for each severity scale are actually fairly
consistently clustered together in the SROC plane. We also
speciﬁcally chose to include studies with direct head-to-head
evaluation of PSI and the CURB-65-related scoring systems
within the same patient population so that heterogeneity would
be minimised when comparing different severity scales.
Although we used a comprehensive search strategy, some
retrieved papers had to be excluded because raw mortality data
were not given or there was insufﬁcient information for us to
work out the number of deaths from the reported sensitivity or
speciﬁcity. Two notable studies had to be excluded for not
fulﬁlling our eligibility criteria: the very ﬁrst PSI-based article
studied patients from 1989 to 1994 which is a very different
time period from that of the CURB-65-related studies that
began around 1999,6 while a recent German study of 388 406
patients reported only on inpatient deaths rather than mortality
at 4e8 weeks of follow-up.7 We did not have the resources to
evaluate non-English publications and we chose to include only
peer-reviewed published literature.
We were unable to properly assess the quality of the included
studies owing to the lack of detail in reporting of key areas such
as the methods used in conﬁrming the outcomes and the anti-
biotic regimens. Only a few studies provided information on the
treatment pathways, and it is possible that different treatment
regimens may have contributed to the substantial heterogeneity
seen here. For instance, variations in antibiotic use and antibiotic
resistance, availability of chest specialists and intensive care beds
could have affected mortality outcomes and performance of the
severity scale.
CONCLUSION
Our ﬁndings suggest that the PSI and CURB-65 scoring systems
perform well at identifying patients with pneumonia who have
a low risk of death. However, it is also clear that all four prog-
nostic scales have limitations and should only be used in
conjunction with careful clinical judgement when making
a management decision. Further research should focus on iden-
tifying the individual characteristics that account for differences
among the four scoring systems so that further reﬁnements can
be made to enable more accurate risk classiﬁcation and treatment
of patients with pneumonia.
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